tirzepatide surpass cvot An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists SURPASS-CVOT trial: Tirzepatide was non-inferior
Pay in 4 interest-free payments of $5.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


























